Amedisys (NASDAQ:AMED) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Thursday.
A number of other research analysts have also weighed in on the company. SunTrust Banks reissued a “buy” rating and set a $60.00 target price on shares of Amedisys in a report on Monday, October 9th. Royal Bank of Canada reissued a “hold” rating on shares of Amedisys in a report on Monday, October 23rd. Robert W. Baird boosted their target price on Amedisys from $50.00 to $60.00 and gave the stock a “neutral” rating in a report on Friday, November 10th. Jefferies Group reissued a “buy” rating and set a $60.00 target price on shares of Amedisys in a report on Thursday, October 12th. Finally, William Blair reissued an “outperform” rating on shares of Amedisys in a report on Tuesday, November 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $61.00.
Amedisys (AMED) opened at $51.10 on Thursday. The firm has a market capitalization of $1,720.00, a P/E ratio of 40.56, a price-to-earnings-growth ratio of 1.13 and a beta of 0.71. Amedisys has a 1 year low of $42.05 and a 1 year high of $65.91. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.33 and a current ratio of 1.33.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Tuesday, November 7th. The health services provider reported $0.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.54 by $0.02. The firm had revenue of $380.20 million for the quarter, compared to analyst estimates of $384.59 million. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The business’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.36 EPS. sell-side analysts forecast that Amedisys will post 2.24 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of AMED. Riverhead Capital Management LLC grew its holdings in Amedisys by 75.5% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock valued at $121,000 after buying an additional 831 shares in the last quarter. Federated Investors Inc. PA grew its holdings in Amedisys by 2.3% in the 2nd quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock valued at $122,000 after buying an additional 44 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new position in Amedisys in the 3rd quarter valued at $205,000. SG Americas Securities LLC grew its holdings in Amedisys by 48.7% in the 2nd quarter. SG Americas Securities LLC now owns 3,743 shares of the health services provider’s stock valued at $235,000 after buying an additional 1,226 shares in the last quarter. Finally, Amalgamated Bank acquired a new position in Amedisys in the 2nd quarter valued at $246,000. 94.44% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “BidaskClub Downgrades Amedisys (AMED) to Strong Sell” was posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://transcriptdaily.com/2018/01/11/bidaskclub-downgrades-amedisys-amed-to-strong-sell.html.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.